Interferon-beta-1b increases serum interleukin-12 p40 levels in primary 
progressive multiple sclerosis patients

Bahner, D; Klucke, C; Kitze, B; Elitok, E; Bogumil, T; Dressel, A; Tumani, H; Weber, F; Poser, S; Bitsch, A-

Item

ITEM ACTIONSEXPORT

Add to Basket

Local TagsRelease HistoryDetailsSummary

Released

Journal Article

Interferon-beta-1b increases serum interleukin-12 p40 levels in primary progressive multiple sclerosis patients

MPS-Authors

Bahner, D
Max Planck Institute of Psychiatry, Max Planck Society;

Klucke, C
Max Planck Institute of Psychiatry, Max Planck Society;

Kitze, B
Max Planck Institute of Psychiatry, Max Planck Society;

Elitok, E
Max Planck Institute of Psychiatry, Max Planck Society;

Bogumil, T
Max Planck Institute of Psychiatry, Max Planck Society;

Dressel, A
Max Planck Institute of Psychiatry, Max Planck Society;

Tumani, H
Max Planck Institute of Psychiatry, Max Planck Society;

Weber, F
Max Planck Institute of Psychiatry, Max Planck Society;

Poser, S
Max Planck Institute of Psychiatry, Max Planck Society;

Bitsch, A-
Max Planck Institute of Psychiatry, Max Planck Society;

External Resource

No external resources are shared

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

There are no public fulltexts stored in PuRe

Supplementary Material (public)

There is no public supplementary material available

Citation

Bahner, D., Klucke, C., Kitze, B., Elitok, E., Bogumil, T., Dressel, A., et al. (2002). Interferon-beta-1b increases serum interleukin-12 p40 levels in primary progressive multiple sclerosis patients. Neuroscience Letters, 326(2), 125-128.

Cite as: https://hdl.handle.net/11858/00-001M-0000-000E-A1C1-C

Abstract

Serum levels of interleukin-12 heterodimer (IL-12p70) and its homodimeric subunit (IL-12p40) were analyzed by enzyme-linked immunosorbent assay in 18 patients with primary progressive multiple sclerosis (MS) during 3 months before and 3 months under treatment with interferon-beta-1b (IFNbeta-1b, Betaferon(TM), eight million units (MIU) every other day subcutaneously). Median IL-12p40 levels in MS patients before treatment (66.5 and 63.9 pg/ml) were not elevated compared to 18 healthy controls. IL-12p40 significantly increased during treatment (P < 0.0001, median 105.3 pg/ml after 1 month and 95.3 pg/ml after 3 months). Detectable serum levels of IL-12p70 before therapy were only found in one patient. IL-12p70 did not increase during treatment. These data show that immunological processes may also play a role in primary progressive MS and that IFNbeta-1b has an immunomodulating effect in this particular MS subtype. (C) 2002 Published by Elsevier Science Ireland Ltd